The resort's Ocean Course will be the longest venue in major golf history at 7,876 yards, 135 more than the mark set by Erin Hills when it hosted the 2017 US Open.
China divorces drop 70% after controversial ‘cooling off’ lawLaw requires couples to wait 30 days before formalising divorce – but some say it has made young people more likely to avoid marriage China’s marriage rate is declining. The number of divorces also plummeted at the start of this year. Photograph: Héctor Retamal/AFP/Getty Images
Daniel Sturridge gave Liverpool a first-half lead but Sevilla fought back to win 3-1.
Parent trap: why the cult of the perfect mother has to endWorldwide, mothers are overworked, underpaid, often lonely and made to feel guilty about everything from epidurals to bottle feeding. Fixing this is the unfinished work of feminism ‘Mothers are trying too hard, and society is not trying nearly hard enough.’ Photograph: ChristinLola/Getty Images/iStockphoto
Weatherwatch: how Rwanda’s climate differs from rest of east AfricaThe whole country lies at a higher altitude than virtually anywhere in England A view of the downtown skyline of Kigali, the capital of Rwanda. Photograph: Alamy
‘No new investment in fossil fuels’ demands top energy economistGovernments must close gap between net zero rhetoric and reality, says head of International Energy Agency The UK is licensing new oil and gas fields in the North Sea. Photograph: Jonathan Nackstrand/AFP/Getty Images
Sales of peat compost to gardeners to be banned from 2024Funding for restoration of peatlands and tripling of tree planting in England also announced Crowle Moor and Thorne Moor national nature reserve in Yorkshire. The UK’s peatlands store three times as much carbon as the nation’s forests. Photograph: Les Gibbon/Alamy
Johnson’s voter ID checks are not about electoral fraud, they’re about powerBritain’s elections have a clean bill of health, and yet the government is wilfully hindering people’s right to vote Ballots are counted in Cardiff during the 2019 general election. Photograph: Matthew Horwood/Getty Images
Long Covid symptoms ease after vaccination, survey findsExclusive: Fifty-seven per cent of people with illness say they were better overall after jabCoronavirus – latest updatesSee all our coronavirus coverage The results could reassure those with long Covid that they are unlikely to suffer a worsening of symptoms after vaccination. Photograph: WPA/Getty Images
The study looked at approximately 1,000 factories that make the raw materials for single-use products.
A survey of 2,000 employers found 63% intend to boost “hybrid working” to improve working lives post-pandemic. Is it as easy as it sounds?
A ban on gas boilers from 2025 is one step to reach net-zero emissions by 2050, say energy experts.
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
The world has a viable pathway to building a global energy sector with net-zero emissions in 2050, but it is narrow and requires an unprecedented transformation of how energy is produced, transported and used globally, the International Energy Agency said in a landmark special report released today.
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, today announced the launch of iBASIS Carrier Voice for Teamwork, enabling carriers such as China Telecom Europe (CTE), a leading provider to European multinationals, to serve Enterprise customers with much needed cloud-based PBX functionality for their collaboration platforms.
OTTAWA — Canada's first homegrown vaccine for COVID-19 is showing promising antibody results in hundreds of participants in a Phase 2 trial and could be ready for a final authorization request this summer. Nathalie Landry, the executive vice-president for scientific and medical affairs for Medicago, said the vaccine appears to produce 10 times the antibodies as are seen in people who have had COVID-19. "It's very good news," said Landry. "So based on these results, let's say we're quietly confident that we will be in a position to demonstrate good efficacy of the vaccine." The results are not yet peer-reviewed but Landry said other vaccines in use showed a direct correlation between the level of antibodies produced and their effectiveness against COVID-19. A Phase 3 trial for Medicago with 30,000 volunteers is already underway in Canada, the United States and the United Kingdom, and will expand to Brazil this week. The Phase 3 trial is the final step before Health Canada can decide whether to approve the vaccine or not, something Landry hopes can happen this summer. If approved, the Medicago vaccine is likely to be the first COVID-19 shot produced in Canada in any way. The bulk material will mainly be manufactured at Medicago's North Carolina facility, but the vials are filled and finished with the GlaxoSmithKline pandemic adjuvant in Canada. An adjuvant is a substance used in vaccines to help aid in the immune response. A new manufacturing plant in Quebec that could make most of the bulk material in Canada is still under construction. Landry said the initial in-service date of 2024 has been tentatively moved up a year to 2023. Canada signed a deal in October to buy 20 million doses of Medicago's vaccine, with an option for 56 million more. But most Canadians will be vaccinated before Medicago is approved, leaving its role in Canada unclear. "We have been discussing that situation with the Canadian government," said Landry. She said the most likely scenario is for booster shots. Canada could also donate the 20 million doses it purchased to the global COVAX vaccine-sharing alliance. Landry said there are some discussions about testing Medicago as a mix-and-match vaccine for second doses but acknowledged there may not be time to complete that now. Most Canadians should be fully vaccinated by the end of the summer. Canada has authorized four vaccines to date and 45 per cent of the population has received at least one dose. To date, about two-thirds have been given Pfizer-BioNTech, one-fifth have received Moderna and the rest Oxford-AstraZeneca. Johnson & Johnson was approved in March but hasn't been used in Canada yet. Medicago's Phase 2 trial tested the virus-like particle vaccine on about 900 volunteers in Canada and the United States. One-third of the group were healthy adults between 18 and 64, one-third were over the age of 65, and the remaining third were adults with existing health conditions that might make them at higher risk if they get infected with COVID-19. Only results for healthy adults and seniors are reported now, with results for those with existing health conditions still to come. Overall side effects at the time of vaccination were reported as mild and very short-lived. Seniors didn't see as robust an immune response to one dose as adults between 18 and 64, but both groups showed similar levels of antibodies after a second dose. The Medicago shot is a virus-like particle vaccine, which grows a virus that resembles the SARS-COV-2 virus but doesn't contain its genetic material and therefore can't multiply or make you sick. Usually virus-like particle vaccines, like those used against the human papillomavirus or HPV, are grown in yeast or bacteria. Medicago's technology grows the particles in a plant that is a relative of the common tobacco plant. This report by The Canadian Press was first published May 18, 2021. Mia Rabson, The Canadian Press
Series D investment round led by leading global growth equity firm General Atlantic, with the support of Generation Investment Management, brings Back Market past unicorn territory and further establishes the refurbished sector's important place in the consumer electronics landscape New York, New York--(Newsfile Corp. - May 18, 2021) - Just three years after launching in North America, Back Market, the leading global dedicated refurbished electronics marketplace, today announced an investment round of $335 million led ...
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 18 May 2021 Disclosure of received notification of Bank of Montreal Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification of Bank of Montreal. Notification of Bank of Montreal On 12 May 2021, Fagron received a notification that the shareholding of Bank of Montreal had fallen below the disclosure threshold of 3% (the lowest threshold) on 10 May 2021 as the result of the disposal of voting securities or voting rights.The notification is made by a ‘parent undertaking or a controlling person’.On 10 May 2021, Bank of Montreal held a total of 319,975 voting rights.Based on the denominator of 72,477,654 (total number of voting rights), Bank of Montreal held on 10 May 0.44% of the total number of voting rights.The notification of Bank of Montreal and the chain of controlled undertakings through which the holding is effectively held, can be viewed on investors.fagron.com via this link. In the event of differences between the English translation and the Dutch original of this press release, the latter prevails. For more informationConstantijn van RietschotenChief Communications OfficerTel. +31 6 53 69 15 firstname.lastname@example.org Please open the link below for the press release:Disclosure of received notification of Bank of Montreal
eureKARE launches with $60 million to build and finance next generation biotech companies in Europe $60 million Series A capital to finance and build disruptive European biotechnology companies in two cutting-edge fields of research: the microbiome and synthetic biology Biotech start-up studio model to select and nurture high quality European innovation with revolutionary potential to maximise opportunities for investors and scientists for the benefit of patients eureKARE is guided by influential founder, Alexandre Mouradian, accompanied by a highly skilled team and an international Scientific Advisory Board of renowned experts Paris, France – 18 May 2021: eureKARE ("the Company"), a pioneering new company focused on financing and building next generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, today announces its launch with a $60 million Series A financing. The financing was supported by high-net worth investors and family offices. eureKARE is focused on two emerging and cutting-edge fields of research that have the potential to disrupt and revolutionize the life sciences industry: the microbiome and synthetic biology. Up to 90% of all diseases can be linked to the dysfunction and imbalance of the microbiome with the field forecast to reach $1.6 billion by 2028 at a CAGR of 21%. Synthetic biology, which comprises gene and cell therapy and industrial applications such as data storage and bioproduction, has seen huge advances in recent years and is expected to have far-reaching implications on the life sciences and other industries and for patients. It is forecast to reach $57 billion by 2028 at a CAGR of 25% per year. Gene therapies alone already generate c.$4 billion revenues with huge potential in gene editing, siRNA, mRNA, and is forecast to reach c.$10 billion by 2028. Europe’s scientists are at the forefront of microbiome and synthetic biology research due to the innovative work and thought leadership taking place at prestigious universities and research centers. eureKARE believes there is a tremendous opportunity to industrialize this translational research by building bridges between academia and industry. Rodolphe Besserve, Chief Executive Officer of eureKARE, commented: “European science remains under exploited compared to countries like the US, with the gap between academia and big pharma widening over the years. eureKARE aims to build bridges between these two bodies to create and support new ventures. eureKARE has assembled an expert team and, together with our top-notch Scientific Advisory Board, we want to create a unique ecosystem of ideation and cross-fertilization of expertise to build successful companies.” eureKARE has a two-step investment approach to deliver long-term value creation built around the two major inflection points in pharmaceutical development. The Company supports translational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology). These studios are designed to select and nurture high quality European science and create a unique ecosystem, putting resources and expertise behind scientists and concepts to create new companies. The Company also intends to invest in more mature biotech companies (Series B or after) and will systematically propose to offer some liquidity to early investors, thereby addressing a critical need in the European biotech field. eureKARE will create 3-5 new ventures a year and invest in 3-5 existing companies. This perfect mix of early-stage ventures with high growth potential and more mature de-risked companies mitigates risk for shareholders. eureKARE has a rapidly growing portfolio comprising three exciting ventures to date: Stellate Therapeutics in the gut-brain axis field, the XNA technology company Omne Possibile and NovoBiome, a discovery platform dedicated to the gut-liver axis. “Each of these companies has the potential to offer disruptive solutions in its chosen domain. These are perfect examples of what eureKARE wants to do. Thinking outside the box is in our DNA. The rapid COVID-19 vaccine development has shown the power of human ingenuity and this model will be a core inspiration for us as we progress,” added Rodolphe Besserve. eureKARE is guided by influential founder, Alexandre Mouradian, along with a pan-European team led by renowned biotech expert Rodolphe Besserve. eureKARE’s Scientific Advisory Board is composed of eight international leading lights in their respected knowledge base, who will support the company in all of its strategic and investment decisions. Commenting on the launch, Alexandre Mouradian, Founder & Chairman of eureKARE, said: “Europe is at the forefront of microbiome and synthetic biology research and it is vital to find innovative new investment approaches to support the next wave of life science entrepreneurs. Through eureKARE’s pioneering approach, we are poised to identify, select and nurture the very best European science to create exciting new companies with the potential to disrupt and revolutionize the life sciences industry for the benefit of patients, while delivering shareholder value.” -End- About eureKAREeureKARE is a pioneering new company focused on financing and building next generation biotechnology companies in the cutting-edge fields of the microbiome and synthetic biology. eureKARE has a two-step investment approach to deliver long-term value creation. The Company supports translational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology). The Company also intends to invest in more mature biotech companies and will systematically propose to offer some liquidity to early investors, thereby addressing a critical need in the European biotech field. Guided by its influential founder, Alexandre Mouradian, and a pan-European team, eureKARE has a rapidly growing portfolio of companies that have the potential to disrupt the life sciences industry. eureKARE is headquartered in Luxembourg, with a presence in France & Belgium. For more information visit: https://eurekare.eu/ About NovoBiomeNovoBiome is a drug discovery company focused on the critical nexus of liver, intestinal diseases and the gut microbiome. It is developing breakthrough Live Biotherapeutics Products (LBPs), a novel and emerging class of drugs containing living micro-organisms that have a positive influence on the health and physiology of the host. NovoBiome’s first LBP drug candidate, ADC-001, targets potential first-in-class therapies for hepatic conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). The Company is developing an ex-vivo research and discovery platform, NovoSift®, designed to mimic human intestinal physiology that will unlock new insights into disease pathophysiology, novel drug targets, compounds and LBP drug candidates. NovoBiome is headquartered in France. For more information, please visit: www.novobiome.eu About Omne PossibileOmne Possibile is a pioneering, global technological leader in XNA, creating customizable structures to outperform current DNA and RNA technologies. Its goal is to harness the transformative power of XNA in areas including healthcare, information technology and smart materials. The Company’s initial focus is on development of XNA polymers for information storage and XNA building blocks for improved messenger therapeutics. Omne Possibile has R&D hubs in Leuven, Belgium, and Basel, Switzerland. It was founded by leading European synthetic biologists and is supported by a world class scientific advisory board. For more information, please visit www.omnepossibile.comAbout Stellate TherapeuticsStellate Therapeutics is a private global biotechnology company that develops small molecules produced by the microbiome into first-in-class therapies for neurological diseases (Parkinson and Alzheimer diseases). Stellate is also evaluating a portfolio of new drug candidates in other conditions, with capabilities across discovery, screening, production and diagnostic development. For more information, visit www.stellate-tx.com. ContacteureKARE SAMarina Shapochnik, Head Investor Relationsmarina.email@example.com Consilium Strategic CommunicationsAmber Fennell, Jonathan Birt, Melissa Gardiner, Carina Jurs +44 (0) 203 709 firstname.lastname@example.org
Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, today announced the signing of a share purchase agreement for the sale of 100% of its 128 megawatt VSM2 and 59 megawatt VSM4 wind farms to the Brazilian utility Copel. The actual sale is scheduled for November 30, 2021, once the conditions precedent have been met. Over the past years, Voltalia has pursued a strategy consisting in developing a high volume of competitive projects with the view of keeping some projects while partnering with strategic partners for others. As of today, Voltalia owns 624 megawatts of operating wind farms and 187 megawatts of wind farms under construction at Serra Branca in Brazil, the world's largest wind-and-solar complex, with a potential of 2.4 gigawatts, developed entirely by Voltalia. In addition, Voltalia owns wind, solar and hybrid assets in operation and in construction located in the Brazilian states of Rio Grande do Norte, Bahia and Amapá, for a total of 223 megawatts. In parallel, Voltalia develops a pipeline of future solar, wind and hydro projects representing a total of 5,1 gigawatts as of end of 2020. This pipeline has been increasing over the past years, and important development milestones achieved since the beginning of 2021 will significantly expand further this pipeline. Voltalia will therefore continue to sell a big portion of its future projects. The VSM2 and VSM4 wind farms are both part of the Serra Branca cluster. The wind farms will use the infrastructure developed and built by Voltalia, including the 500 kV transmission lines. VSM2 has just completed its commissioning, while VSM4, currently under construction, is expected to begin operations in June. Voltalia's teams will continue to operate and maintain both plants after the sale to Copel. Copel is one of Brazil's leading utilities, serving 4.8 million customers in 395 municipalities and 1,113 localities (districts, towns and villages). This acquisition is in line with the Company’s sustainable growth strategy in the field of renewable energy and is fully consistent with its recent investment policy approved earlier this year. Copel is listed on the São Paulo, New York and Madrid stock exchanges and its main shareholder is the State of Paraná. A long-time partner of Voltalia, with a minority stake in Voltalia's SMG wind farm (108 megawatts) since 2015, Copel was recently one of the counterparties of the long-term power sales agreements totaling 270 megawatts for the SSM 1&2 solar farms. "This share purchase agreement shows our partners' renewed confidence in our quality projects and our continuous strategy to develop a large amount of projects, providing additional revenues for our Services activity. VSM2 and VSM4 will continue to create value for the Group, as the maintenance of both wind farms will be handled by Voltalia's teams," said Sébastien Clerc, Voltalia’s CEO. The Serra banca cluster as of today: Ownership Technology Status Capacity (in MW)Before transaction Capacity (in MW)After transaction Developed and owned by Voltalia Wind Operating 624 496 Developed and sold with services by Voltalia Wind Operating 273 401 Sub total 897 897 Developed and owned by Voltalia Wind Construction 187 128 Developed and sold with services by Voltalia Wind Construction 301 360 Sub total 488 488 Developed & Owned by Voltalia Solar Ready to build with PPA 530 530 Under Development by Voltalia Solar & Wind Development ~500 ~500 Grand Total ~2 400 ~2 400 Next meeting : General Assembly 2021, 19 May 2021 at 3pm About Voltalia (www.voltalia.com) Voltalia is an international player in the renewable energy sector. The Group produces and sells electricity generated from wind, solar, hydraulic, biomass and storage facilities that it owns and operates. Voltalia has generating capacity in operation and under construction of more than 1.4 GW and a portfolio of projects under development representing total capacity of 9.7 GW. Voltalia is also a service provider and supports its investor clients in renewable energy projects during all phases, from design to operation and maintenance. As a pioneer in the corporate market, Voltalia provides a global offer to private companies, ranging from the supply of green electricity and energy efficiency services to the local production of their own electricity. The Group has more than 1,130 employees and is present in 20 countries on 4 continents and is able to act worldwide on behalf of its clients. Voltalia is listed on the regulated market of Euronext Paris, compartment B (FR0011995588 – VLTSA) and is part of the Enternext Tech 40 and CAC Mid & Small indices. The Group is also included in the Gaïa-Index, an index for socially responsible midcaps. VoltaliaInvestor Relations: email@example.comT. +33 (0)1 81 70 37 00 ActifinPress Contact: Jennifer Julliajjullia@actifin.fr . T. +33 (0)1 56 88 11 11 Attachment Voltalia signs a share purchase agreement to sell 187-megawatt wind projects to Brazilian utility Copel